Overall Fundamental outlook

* IPCALAB makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

IPCALAB's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 2.627000
forwardPE 25.635342
debtToEquity 16.246000
earningsGrowth 0.136000
revenueGrowth 0.105000
grossMargins 0.655370
operatingMargins 0.132410
trailingEps 29.110000
forwardEps 47.850000

IPCALAB's current ratio of 2.627 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. IPCALAB's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
IPCALAB's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
IPCALAB's low Debt-to-Equity ratio means it is not excessively leveraged, implying a reduced financial risk profile. This suggests IPCALAB maintains a well-balanced financial structure, with more emphasis on equity than debt, ensuring greater flexibility and long-term stability.
Ipca Laboratories Limited's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
IPCALAB's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with IPCALAB anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

IPCALAB's price projections have gradually risen, indicating growing confidence in the company's prospects. This upward trend suggests that analysts expect IPCALAB to continue performing well in the future.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


IPCALAB had 1 sell transactions, while the market price was at 1513.199951171875 per share.No sell transactions were carried out during the period under review.Investors have shown more interest in buying than selling IPCALAB at current price levels, which may point to a positive market sentiment. This could indicate that investors are expecting favorable results from the stock in the near future.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


The recent buy bias from analysts suggests IPCALAB is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, IPCALAB appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.